About Oriel Therapeutics
Oriel Therapeutics is a company based in Morrisville (United States) founded in 2001 was acquired by Sandoz in April 2010.. Oriel Therapeutics has raised $26.5 million across 1 funding round from investors including Sandoz and New Leaf Venture Partners. Oriel Therapeutics operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Morrisville, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Oriel Therapeutics
Oriel Therapeutics has successfully raised a total of $26.5M through 1 strategic funding round. The most recent funding activity was a Series C round of $26.5 million completed in November 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series C — $26.5M
-
First Round
First Round
(16 Nov 2007)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2007 | Amount | Series C - Oriel Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Oriel Therapeutics
Oriel Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Sandoz and New Leaf Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage-agnostic investments in US life sciences are managed.
|
Founded Year | Domain | Location | |
|
Generic and biosimilar pharmaceuticals are developed and distributed globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Oriel Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Oriel Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Oriel Therapeutics Comparisons
Competitors of Oriel Therapeutics
Oriel Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Oriel Therapeutics
When was Oriel Therapeutics founded?
Oriel Therapeutics was founded in 2001 and raised its 1st funding round 6 years after it was founded.
Where is Oriel Therapeutics located?
Oriel Therapeutics is headquartered in Morrisville, United States.
Is Oriel Therapeutics a funded company?
Oriel Therapeutics is a funded company, having raised a total of $26.5M across 1 funding round to date. The company's 1st funding round was a Series C of $26.5M, raised on Nov 16, 2007.
What does Oriel Therapeutics do?
Oriel Therapeutics was established in 2001 in Morrisville, United States, as a specialty pharmaceutical entity focused on respiratory care. Generic alternatives to patented drugs for asthma and chronic obstructive pulmonary disease are developed, utilizing the proprietary Solis disposable dry powder inhaler based on FreePath drug delivery technology. Operations have been conducted as a subsidiary of Sandoz since June 1, 2010.
Who are the top competitors of Oriel Therapeutics?
Oriel Therapeutics's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Who are Oriel Therapeutics's investors?
Oriel Therapeutics has 2 investors. Key investors include Sandoz, and New Leaf Venture Partners.